Pfizer top products by revenue 2024
The graph depicts Pfizer's top 10 products based on revenue in 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's top product was Eliquis. COVID-19 vaccine Comirnaty, on the other hand, showed another dramatic decline in sales from 11.2 billion U.S. dollars in 2023 to 5.4 billion dollars.
Pfizer's top products
Pfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2024, Pfizer generated a total revenue of 63.6 billion U.S. dollars worldwide, with oncology products accumulating some 15.6 billion U.S. dollars.
Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around 3.3 and five billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of 12.9 billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under two billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.
